Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNAi therapeutics - Arbutus

Next Previous
Drug Profile

Research programme: RNAi therapeutics - Arbutus

Alternative Names: LNP-siRNA therapeutics - Arbutus; TKM-ALDH; TKM-GSD; TKM-HTG; TKM-Marburg

Latest Information Update: 17 Apr 2019

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Protiva Biotherapeutics
  • Developer Arbutus Biopharma
  • Class Antihyperlipidaemics; Antineoplastics; Antivirals; Drug withdrawal therapies; Hepatoprotectants; Small interfering RNA
  • Mechanism of Action COPS5 protein inhibitors; RNA interference; WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Alcoholism; Hypertriglyceridaemia; Marburg virus disease; Non-alcoholic steatohepatitis; Solid tumours
  • No development reported Lysosomal storage diseases

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lysosomal storage diseases in USA (Parenteral)
  • 21 Mar 2017 Suspended - Preclinical for Alcoholism (TKM ALDH) in USA (Parenteral) (Arbutus 10-K 2017)
  • 21 Mar 2017 Suspended - Preclinical for Hypertriglyceridaemia (TKM HTG) in USA (Parenteral) (Arbutus 10-K 2017)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top